Statistical analyses The normality of data was assessed by Shapiro-Wilk’s test. Levene’s test was used to analyze the homogeneity of variances. Two-way analysis of variance (ANOVA) for repeated measures was used for comparisons between conditions (CAF and PLA) and over time. The Bonferroni post hoc test was used when a significant F ratio was found for the main or interaction effect. A significance level of 5% was used

Saracatinib mouse for all analyzes. Additionally, the practical inference based on magnitudes was also applied [22]. The chance of a given value to be beneficial (positive) or detrimental (negative) effect [e.g., higher or lower than the smallest worthwhile changes (0.20 multiplied by the initial standard deviation based on the effect size)] was calculated [23]. Thus, the change was assessed

qualitatively as follows: <1% almost certainly not; 1-5% very unlikely, 5-25% unlikely, 25-75% possible, 75-95% likely, 95-99% very likely and > 99% almost certainly yes. When the negative and positive values showed results greater than 10%, the inference was considered inconclusive. The effect size (Cohen’s d) was also calculated for the time trial performance and interpreted using the recommendations suggested by Hopkins et al. [22] as follows: 0 = Trivial; 0.2 = Small; 0.6 = Moderate; 1.2 = Large; 2.0 = Very large; 4.0 = Nearly perfect. Results Information on power, speed, pedaling cadence, HR and 20-km time trial test duration for PLA and CAF conditions are presented in Table 1. No significant differences were observed between CAF and PLA concerning BIBF 1120 nmr below HR and all the performance variables (P > 0.05). The results of the qualitative analysis proved inconclusive (unclear). The effect size was 0.06, being considered trivial. Power output and speed at every two kilometers in the 20-km time-trial, for CAF and PLA, are illustrated in Figure 1. Although a similar Chk inhibitor response

was observed among groups (P > 0.05), a significant distance main effect in the last two kilometers of the test was observed with increased power and speed (P < 0.001). However, no significant group main effect or group by moment interaction was identified (P > 0.05). Table 1 Cycling performance indicators during the 20-km time trials, after acute ingestion of CAF (n = 13) or PLA (n = 13). Values are expressed as mean ± standard deviation   Condition   Variables PLA CAF P Power (watts) 206.9 ± 28.5 204.6 ± 43.9 0.79 Speed (km.h−1) 33.5 ± 1.8 33.3 ± 2.8 0.72 Cadence (rpm) 105.3 ± 8.4 103.4 ± 4.1 0.96 HR (beats.min−1) 171 ± 9.9 171 ± 8.0 0.94 Duration (s) 2191 ± 157.6 2181 ± 193.9 0.61 % difference (IC 90%) −10.1 (−45 to 24.9) % difference positive/trivial/negative 2/85/12 Qualitative Inference Unclear CAF = caffeine; PLA = placebo. Figure 1 Responses of power and speed on 20-km time-trial test under the conditions CAF (n = 13) and PLA (n = 13). *P < 0.05 vs. 20 km. Significant main effect of time (P < 0.001).